Fundraising Fox
/Companies
Sign in

Apnimed

NASDAQ: APMD

Cambridge, US · Founded 2017 · Delaware corporation · 4 known investors

Find your way into Apnimed

Sign up to find every way you can get introduced to Apnimed

  • Your email: who you already know at Apnimed, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Apnimed team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients. It is a clinical-stage pharmaceutical company focused on sleep apnea.

BiotechDigital HealthHealthtech

Founders & leadership

Apnimed was founded in 2017 by Lawrence G. Miller.

LGLawrence G. Miller
Lawrence G. MillerFounder
DMDennis Molnar
Dennis MolnarExecutive
BWBarry Wohl
Barry WohlChief Business Officer
KMKetan Mehta
Ketan MehtaHead of Product and Engineering, Connected Wearables
RF
Ron FarquharNamed on SEC filing
GC
Gerald ChanNamed on SEC filing

Board

KLKevin Lind
Kevin LindChief Executive OfficerPresident & CEO at Longboard Pharmaceuticals
CD
Chris DimitropoulosBoard director
FB
Francois BeaubienBoard director
IC
Isaac ChengBoard director
PF
Paul FonteyneBoard director
GS
Gary SenderBoard director

Investors · 4

HEALTHCARE ROYALTY PARTNERSlisted by HEALTHCARE ROYALTY PARTNERSNew York
Morningside GroupreportedHong Kong

How we know: press coverage · Not right? Tell us

Sectoral Asset ManagementreportedMontreal

How we know: funding news · press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$284.3M disclosed across 8 of 9 rounds · 2018–2026

▶$25MraisedMar 2026 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence G. MillerExecutive Officer, Director
  • Paul FonteyneDirector
  • Dennis MolnarExecutive Officer
  • Barry WohlExecutive Officer
  • Joseph C. AvelloneDirector
  • Francois BeaubienDirector
  • Chris DimitropoulosDirector
  • Kevin LindDirector
  • Isaac ChengDirector
  • Gary SenderDirector
  • Ramzi BenamarExecutive Officer
Offering amount
$25M
Amount sold
$25M
First sale
Mar 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35MraisedDec 2025 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin LindDirector
  • Ramzi BenamarExecutive Officer
  • Dennis MolnarExecutive Officer
  • Barry WohlExecutive Officer
  • Chris DimitropoulosDirector
  • Francois BeaubienDirector
  • Paul FonteyneDirector
  • Gary SenderDirector
  • Lawrence G. MillerExecutive Officer, Director
  • Isaac ChengDirector
  • Joseph C. AvelloneDirector
Offering amount
$35M
Amount sold
$35M
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.5MraisedApr 2025 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul FonteyneDirector
  • Barry WohlExecutive Officer
  • Kevin LindDirector
  • Gary SenderDirector
  • Dennis MolnarExecutive Officer
  • Joseph C. AvelloneDirector
  • Lawrence G. MillerExecutive Officer, Director
  • Chris DimitropoulosDirector
  • Francois BeaubienDirector
  • Isaac ChengDirector
Offering amount
$16.5M
Amount sold
$16.5M
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$37.5MofferedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence G. MillerExecutive Officer, Director
  • Francois BeaubienDirector
  • Michael RogersExecutive Officer
  • Dennis MolnarExecutive Officer, Director
  • Isaac ChengDirector
  • Barry WohlExecutive Officer
  • Paul FonteyneDirector
  • Joseph C. AvelloneDirector
  • Chris DimitropoulosDirector
Offering amount
$37.5M
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$79.7MraisedDec 2022 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Barry WohlExecutive Officer
  • Chris DimitropoulosDirector
  • Lawrence G. MillerExecutive Officer, Director
  • Michael RogersExecutive Officer
  • Ruoxi HuDirector
  • Dennis MolnarExecutive Officer, Director
  • Stefan LarsonDirector
  • Isaac ChengDirector
  • Joseph C. AvelloneDirector
Offering amount
$79.7M
Amount sold
$79.7M
First sale
Dec 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$62.5MraisedNov 2022 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Rosy HuDirector
  • Barry WohlExecutive Officer
  • Michael RogersExecutive Officer
  • Chris DimitropoulosDirector
  • Joseph C. AvelloneDirector
  • James GaleotaDirector
  • Isaac ChengDirector
  • Lawrence G. MillerExecutive Officer, Director
  • Dennis MolnarExecutive Officer, Director
  • Stefan LarsonDirector
Offering amount
$62.5M
Amount sold
$62.5M
First sale
Apr 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedMar 2021 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence G. MillerExecutive Officer, Director
  • Dennis MolnarExecutive Officer, Director
  • Joseph C. AvelloneDirector
  • James GaleotaDirector
  • Gerald ChanDirector
  • Barry WohlExecutive Officer
Offering amount
$25M
Amount sold
$25M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedApr 2020 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ron FarquharDirector
  • Lawrence G. MillerExecutive Officer, Director
  • Gerald ChanDirector
  • Barry WohlExecutive Officer
  • Joseph AvelloneDirector
  • Dennis MolnarExecutive Officer, Director
Offering amount
$15M
Amount sold
$15M
First sale
Mar 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$637.2Mvaluation at IPOJul 2026 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 1

MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies working in the same space as Apnimed.

In the news

The Startup Behind The Pill For Sleep Apnea Raises $192 Million In IPOforbes.com · Jul 2026

Frequently asked questions

What does Apnimed do?
Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients. It is a clinical-stage pharmaceutical company focused on sleep apnea.
Who founded Apnimed?
Apnimed was founded by Lawrence G. Miller in 2017.
Who are Apnimed's investors?
Apnimed's investors include Alpha Wave Global, HEALTHCARE ROYALTY PARTNERS, Morningside Group, Sectoral Asset Management.
How much funding has Apnimed raised?
Apnimed has disclosed $284.3M raised across 8 of its 9 known rounds.
Where is Apnimed headquartered?
Apnimed is headquartered in Cambridge, US.